12000-1-AP

antibody from Proteintech Group

Targeting: CCL5 D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Antibody Data

Product number

12000-1-AP

Provider

Proteintech Group

Product name

RANTES antibody

Antibody type

Polyclonal

Description

RANTES antibody (Cat. #12000-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.

Liang Y, He S, Liu Q, Liu T, Tan Y, Peng T, Huang C, Lu X, Zheng S
Biochimica et biophysica acta. Molecular cell research 2024 Oct;1871(7):119781

---

Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis.

Xiong Z, Yu SL, Xie ZX, Zhuang RL, Peng SR, Wang Q, Gao Z, Li BH, Xie JJ, Huang H, Li KW
iScience 2024 May 17;27(5):109674

---

PTBP2-Mediated Alternative Splicing of IRF9 Controls Tumor-Associated Monocyte/Macrophage Chemotaxis and Repolarization in Neuroblastoma Progression.

Tang J, He J, Guo H, Lin H, Li M, Yang T, Wang HY, Li D, Liu J, Li L, Xia H, Zhuo Z, Miao L
Research (Washington, D.C.) 2023;6:0033

---

Identification and Preliminary Clinical Validation of Key Extracellular Proteins as the Potential Biomarkers in Hashimoto's Thyroiditis by Comprehensive Analysis.

Xi Z, Yang T, Huang T, Zhou J, Yang P
Biomedicines 2023 Nov 24;11(12)

---

Targeted Deletion of Rictor in BMSCs Reduces the Biological Activity of K7M2 Cells and Mitigates OS-Induced Bone Destruction.

Lu J, Dai D, Zhang J, Wang R, Miao D, Sun W
Stem cells (Dayton, Ohio) 2023 Jun 15;41(6):672-683

---

Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.

Xu J, Shi Q, Lou J, Wang B, Wang W, Niu J, Guo L, Chen C, Yu Y, Huang Y, Guo W, Lan J, Zhu Y, Ren T, Tang X
Journal for immunotherapy of cancer 2023 Apr;11(4)

---

Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells.

Niu M, Yi M, Dong B, Luo S, Wu K
Annals of translational medicine 2020 Aug;8(15):951

---

Effects of CCL5 on the biological behavior of breast cancer and the mechanisms of its interaction with tumor‑associated macrophages.

An G, Wu F, Huang S, Feng L, Bai J, Gu S, Zhao X
Oncology reports 2019 Dec;42(6):2499-2511